目前,已经上市的免疫检查点抑制剂 PD-1 或 PD-L1 抑制剂共 5 个,即 Tecentriq(Atezolizumab)、Imfinzi(Durvalumab)[2]、Bavencio(Avelumab)[3]、Opdivo(Nivolumab)[4]、Keytruda(Pembrolizumab)[5]。 近日, 瑞士医药巨头罗氏的新星药物 Tecentriq (Atezolizumab),接连获得美国 FDA 和欧洲 EMA 的批准,将广泛用于...
目前，已经上市的免疫检查点抑制剂 PD-1 或 PD-L1 抑制剂共 5 个，即 Tecentriq(Atezolizumab)、Imfinzi(Durvalumab)[2]、Bavencio(Avelumab)[3]、Opdivo(Nivolumab)[4]、Keytruda(Pembrolizumab)[5]。近日， 瑞士医药巨头罗氏的新星药物 Tecentriq (Atezolizumab)，接连获得美国 FDA 和欧洲 EMA 的批准，将广泛用...
and immunotherapy. Iadademstat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as atezolizumab or durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of ...
目前,已经上市的免疫检查点抑制剂 PD-1 或 PD-L1 抑制剂共 5 个,即 Tecentriq(Atezolizumab)、Imfinzi(Durvalumab)[2]、Bavencio(Avelumab)[3]、Opdivo(Nivolumab)[4]、Keytruda(Pembrolizumab)[5]。 近日, 瑞士医药巨头罗氏的新星药物 Tecentriq (Atezolizumab),接连获得美国 FDA 和欧洲 EMA 的批准,将广泛用于...
目前,已经上市的免疫检查点抑制剂 PD-1 或 PD-L1 抑制剂共 5 个,即 Tecentriq(Atezolizumab)、Imfinzi(Durvalumab)[2]、Bavencio(Avelumab)[3]、Opdivo(Nivolumab)[4]、Keytruda(Pembrolizumab)[5]。 近日, 瑞士医药巨头罗氏的新星药物 Tecentriq (Atezolizumab),接连获得美国 FDA 和欧洲 EMA 的批准,将广泛用于...
Heejin Lim1, Sang Hyung Lee1,Yu Jeong Moon1, Hyo Jeong Pyo1, Seong Eon Ryu2, Woori Shin1 &Yong-Seok Heo1 In 2016 and 2017, monoclonal antibodies targeting PD-L1, including atezolizumab, durvalumab, and avelumab, were approved by the FDA for the treatment of multiple advanced cancers....
Durvalumab The risk or severity of adverse effects can be increased when Atezolizumab is combined with Durvalumab. Dyclonine The risk or severity of methemoglobinemia can be increased when Atezolizumab is combined with Dyclonine. Ebola Zaire vaccine (live, attenuated) The therapeutic efficacy of Ebola...
免疫单药治疗——与Tecentriq类似,几款单药获益用于膀胱癌的免疫疗法,ORR较低,一线和二线均在30%以下。局部晚期或转移性膀胱癌不适合顺铂的一线治疗者,NCCN指南推荐帕博利珠单抗和阿塔珠单抗;局部晚期或转移性膀胱癌二线治疗NCCN指南推荐纳武利尤单抗、帕博利珠单抗、阿塔珠单抗、Avelumab和Durvalumab。
6. Imfinzi (durvalumab) [package insert]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2017. 7. Bavencio (avelumab) [package insert]. New York, NY: EMD Serono, Inc, and Pfizer Inc; 2017. 8. Herbst RS, Soria JC, Kowanetz M, et al. Predictive correlates of response to the anti-...
目前,已经上市的免疫检查点抑制剂 PD-1 或 PD-L1 抑制剂共 5 个,即 Tecentriq(Atezolizumab)、Imfinzi(Durvalumab)[2]、Bavencio(Avelumab)[3]、Opdivo(Nivolumab)[4]、Keytruda(Pembrolizumab)[5]。 近日, 瑞士医药巨头罗氏的新星药物 Tecentriq(Atezolizumab),接连获得美国 FDA 和欧洲 EMA 的批准,将广泛用于...